In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

European Notebook: EMA’s 2016 Work Agenda; Clinical Trial Rule Delay; Ireland Benefits From Pfizer Merger

Executive Summary

The European Medicines Agency wants to accelerate clinical development plans with new processes and procedures in 2016 and companies must disclose payments to providers starting mid-year; Ireland and Switzerland look set to grapple with high drug prices, and France's industry wants to reverse the erosion of jobs.

You may also be interested in...



European Notebook: UK To Leave EU; Prices Attract Political Attention; Advanced Therapies Revamp

Brexit vote creates uncertainty about biopharma policies in the UK and how local companies interact with the rest of the world;; antibiotic use decreases in several countries; high prices prompt European Commission review of industry incentives.

'Different Animals With Different Purposes': Putting PRIME And Adaptive Pathways In Context

EMA official gives perspectives on how PRIME and adaptive pathways compare, and how they fit with other programs such as conditional authorization.

EMA Head On Transparency, Affordable Innovation, And What Patients Really Need

EMA will reinforce its role as a global reference authority and help build regulatory capacity in less experienced countries, Guido Rasi says in outlining his five-year priorities for the agency. He hopes regulatory efficiencies might contribute to lower drug prices.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS057353

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel